Secondary amyloidosis complication of Crohn disease treated with infliximab.
10.12701/yujm.2015.32.2.102
- Author:
Min Joo SONG
1
;
Hyo Sang KIM
;
Soyoung PARK
;
Jaekyung CHEON
;
Sojung PARK
;
Ji Young YANG
;
Su Kil PARK
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. skpark@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Crohn disease;
Amyloidosis;
Infliximab
- MeSH:
Adult;
Amyloid;
Amyloidosis*;
Creatinine;
Crohn Disease*;
Female;
Gastrointestinal Tract;
Humans;
Necrosis;
Infliximab
- From:Yeungnam University Journal of Medicine
2015;32(2):102-105
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Secondary systemic (AA) amyloidosis is a severe complication of progressed Crohn disease (CD) characterized by the deposition of amyloid A in body organs and tissues. Various therapeutic approaches have been recommended, however there is still no effective treatment. Recently, several case reports have demonstrated the effects of anti-tumor necrosis factor-alpha therapy in patients with AA amyloidosis associated with CD. We report on a 35-year-old female patient with CD complicated by AA amyloidosis in the gastrointestinal tract and renal involvement, who was treated with infliximab. The infliximab therapy improved the gastrointestinal symptoms and decreased the serum creatinine.
